国际肿瘤学杂志

国际肿瘤学杂志››2013,Vol. 40››Issue (7): 526-529.doi:10.3760/cma.j.issn.1673-422X.2013.07.016

• 综述 •上一篇下一篇

表皮生长因子受体酪氨酸激酶抑制剂联合化疗治疗肺癌的研究进展

张贝贝, 宋正波, 张沂平*

  1. 310022 杭州, 浙江省肿瘤医院化疗中心
  • 出版日期:2013-07-08发布日期:2013-07-08
  • 通讯作者:张沂平 E-mail:zyp@medmail.com.cn E-mail:zyp@medmail.com.cn
  • 基金资助:

    吴阶平医学基金（320.6750.11059，320.6750.11091）卫生部医药卫生科技发展研究中心课题（W2012FZ13）浙江省自然基金（Z13H040257）

Advances in the the epidermal growth factor receptor tyrosine kinase inhibitors combined with chemotherapy for lung cancer treatment

ZHANG Bei-Bei, SONG Zheng-Bo, ZHANG Yi-Ping

  1. Chemotherapy Center, Zhejiang Cancer Hospital, Hangzhou 310022, China
  • Online:2013-07-08Published:2013-07-08
  • Contact:ZHANG Yi-Ping E-mail:zyp@medmail.com.cn

PDF

1408

摘要：表皮生长因子受体（EGFR）酪氨酸激酶抑制剂（EGFR-TKI）对EGFR突变肺癌患者表现出很好的疗效，对于EGFR野生型肺癌患者化疗药物是首选，EGFR-TKI和化疗药物联合在基础研究方面表现出良好的协同作用，而在临床研究方面与其两药联合的时序有关。

关键词:受体, 表皮生长因子,药物疗法,肺肿瘤

Abstract:Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) show good efficacy for the lung cancer patients with EGFR mutations. Chemotherapy drugs are the first choices for the lung cancer patients with EGFR wild-type. In basic research, EGFR-TKIs combination with chemotherapy drugs show good synergy. But in clinical research, the timing of EGFR-TKIs combination with chemotherapy drugs is related to the efficacy.

Key words:Receptor, epidermal growth factor,Drug therapy,Lung neoplasms